Examining medicine shortages and their consequences through economic, clinical, and economic lens
A study on medicine shortages in the Netherlands found that disease and costs were the two most affected elements, with 30% and 20% of shortages rated high on these elements, respectively. The study used a framework of economic, clinical, and patient outcomes to assess the impact of medicine shortages on patients. Direct impact, represented by alternative product and disease, was rated high for 30% of the shortages, while indirect impact, represented by costs, susceptibility, and number of patients, was rated high for 17% of the shortages. No significant differences in impact scores were found based on product characteristics.
Recent Posts
Pharmaceutical Innovation Benefits Driving Socioeconomic Returns in Europe
Pharmaceutical innovation benefits extend well beyond clinical gains, delivering €5.67 in socioeconomic value for every additional euro spent on newer therapies across 29 European countries from 2014 to 2024. By reducing premature mortality, cutting hospital stays, and increasing workforce partic...
Recommendation for Teplizumab Type 1 Diabetes Routine Use
Teplizumab for Type 1 Diabetes now has a clear route to routine NHS use after NICE recommended the therapy for delaying progression from stage 2 to stage 3 disease in people aged 8 and older. The decision, dependent on a confidential commercial discount, offers families more time before insulin d...
Mapping Vulnerable Elderly Care in the Netherlands
As the Netherlands confronts rapid societal aging, effective vulnerable elderly care has become an urgent policy priority. One in four community-dwelling adults aged 65 and older lives with vulnerable health, according to Longitudinal Aging Study Amsterdam (LASA) data, marking a critical target g...